PADI4 and glioblastoma: Figure 2 furthermore shows representative nanoparticle tracking analysis (NTA) profiles for EV size distribution of LN18 and LN229 control and PAD isozyme-specific treated GBM cells (Figure 2A–H), alongside characterisation of EVs by western blotting using the EV-specific markers CD63 and Flot-1; the absence of β-actin in EVs was assessed to rule out cell-contamination (Figure 2I).